{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:45:53Z","timestamp":1762101953181,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2016.10.034","type":"journal-article","created":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T13:00:27Z","timestamp":1482238827000},"page":"7443-7450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency"],"prefix":"10.1016","volume":"37","author":[{"given":"K.S.","family":"Vannice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.K.","family":"Giersing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.C.","family":"Kaslow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.P.","family":"Durbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hombach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.10.034_b0005","unstructured":"World Health Organization. WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations; 2016. Available at: http:\/\/www.who.int\/mediacentre\/news\/statements\/2016\/1st-emergency-committee-zika\/en\/."},{"key":"10.1016\/j.vaccine.2016.10.034_b0010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(16)00320-2","article-title":"Zika virus and microcephaly: why is this situation a PHEIC?","volume":"387","author":"Heymann","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.10.034_b0015","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMsr1604338","article-title":"Zika virus and birth defects-reviewing the evidence for causality","volume":"374","author":"Rasmussen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.034_b0020","unstructured":"World Health Organization. WHO and experts prioritize vaccines, diagnostics and innovative vector control tools for Zika R&D; 2016. Available at: http:\/\/www.who.int\/mediacentre\/news\/notes\/2016\/research-development-zika\/en\/."},{"key":"10.1016\/j.vaccine.2016.10.034_b0025","unstructured":"World Health Organization. WHO vaccine pipeline tracker; 2016. Available at: http:\/\/www.who.int\/immunization\/research\/vaccine_pipeline_tracker_spreadsheet\/en\/."},{"key":"10.1016\/j.vaccine.2016.10.034_b0030","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature18952","article-title":"Vaccine protection against Zika virus from Brazil","volume":"536","author":"Larocca","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.10.034_b0040","unstructured":"World Health Organization. Zika virus vaccine product development; 2016. Available at: http:\/\/www.who.int\/immunization\/research\/development\/zika\/en\/."},{"key":"10.1016\/j.vaccine.2016.10.034_b0045","unstructured":"World Health Organization. WHO consultation on considerations for regulatory expectations of Zika vaccines for use during an emergency; 2016. Available at: http:\/\/www.who.int\/immunization\/research\/development\/zika\/en\/index1.html."},{"key":"10.1016\/j.vaccine.2016.10.034_b0050","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.celrep.2016.07.049","article-title":"Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype","volume":"16","author":"Dowd","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2016.10.034_b0055","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.10.034_b0060","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJMp1602708","article-title":"Zika virus as a cause of neurologic disorders","volume":"374","author":"Broutet","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.034_b0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12916-016-0601-y","article-title":"Zika virus and neurologic autoimmunity: the putative role of gangliosides","volume":"14","author":"Anaya","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2016.10.034_b0070","doi-asserted-by":"crossref","first-page":"406-A","DOI":"10.2471\/BLT.16.176990","article-title":"Defining the syndrome associated with congenital Zika virus infection","volume":"94","author":"Costello","year":"2016","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2016.10.034_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1605367","article-title":"Zika and the risk of microcephaly","volume":"375","author":"Johansson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.034_b0080","article-title":"Zika virus disease in Colombia \u2013 preliminary report","author":"Pacheco","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.034_b0085","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1602412","article-title":"Zika virus infection in pregnant women in Rio de Janeiro \u2013 preliminary report","author":"Brasil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.034_b0090","doi-asserted-by":"crossref","first-page":"915","DOI":"10.15585\/mmwr.mm6534e2","article-title":"Likely sexual transmission of Zika virus from a man with no symptoms of infection \u2013 Maryland, 2016","volume":"65","author":"Brooks","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2016.10.034_b0095","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.tmaid.2016.07.002","article-title":"Non-vector-borne transmission of Zika virus: a systematic review","volume":"14","author":"Grischott","year":"2016","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.034_b0100","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev-immunol-031210-101315","article-title":"Immune response to dengue virus and prospects for a vaccine","volume":"29","author":"Murphy","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2016.10.034_b0105","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3201\/eid1408.080287","article-title":"Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007","volume":"14","author":"Lanciotti","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.034_b0110","article-title":"Dengue virus antibodies enhance Zika virus infection","author":"Paul","year":"2016","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2016.10.034_b0115","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni.3515","article-title":"Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus","volume":"7","author":"Dejnirattisai","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2016.10.034_b0120","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1073\/pnas.1607931113","article-title":"Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus","volume":"113","author":"Priyamvada","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.10.034_b0125","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.aaf8505","article-title":"Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection","volume":"353","author":"Stettler","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.10.034_b0130","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01123-16","article-title":"Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus","volume":"7","author":"Swanstrom","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2016.10.034_b0135","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.16.30203","article-title":"High specificity of a novel Zika virus ELISA in European patients after exposure to different flaviviruses","volume":"21","author":"Huzly","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2016.10.034_b0140","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1602113","article-title":"Zika virus","volume":"374","author":"Petersen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.034_b0145","doi-asserted-by":"crossref","first-page":"474","DOI":"10.15585\/mmwr.mm6518e1","article-title":"Interim guidance for Zika virus testing of urine \u2013 United States, 2016","volume":"65","author":"Centers for Disease Control and Prevention","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2016.10.034_b0150","unstructured":"World Health Organization. Laboratory testing for Zika virus infection: interim guidance 23 March 2016; 2016. Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/204671\/1\/WHO_ZIKV_LAB_16.1_eng.pdf."},{"key":"10.1016\/j.vaccine.2016.10.034_b0155","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.vaccine.2016.03.076","article-title":"Status of research and development of vaccines for chikungunya","volume":"34","author":"Smalley","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.034_b0160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.aag0219","article-title":"Countering Zika in Latin America","volume":"353","author":"Ferguson","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.10.034_b0165","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8160","article-title":"Assessing the global threat from Zika virus","volume":"353","author":"Lessler","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.10.034_b0180","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1016\/j.vaccine.2015.09.053","article-title":"Next generation dengue vaccines: a review of the preclinical development pipeline","volume":"33","author":"Vannice","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.034_b0185","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.aah6157","article-title":"Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys","volume":"353","author":"Abbink","year":"2016","journal-title":"Science"},{"year":"2014","series-title":"Safety of immunization during pregnancy: a review of the evidence","author":"World Health Organization","key":"10.1016\/j.vaccine.2016.10.034_b0190"},{"key":"10.1016\/j.vaccine.2016.10.034_b0195","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.034_b0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.aai9137","article-title":"Rapid development of a DNA vaccine for Zika virus","volume":"354","author":"Dowd","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.10.034_b0205","doi-asserted-by":"crossref","first-page":"e0004682","DOI":"10.1371\/journal.pntd.0004682","article-title":"Characterization of Lethal Zika virus infection in AG129 mice","volume":"10","author":"Aliota","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.10.034_b0210","doi-asserted-by":"crossref","first-page":"e0004695","DOI":"10.1371\/journal.pntd.0004695","article-title":"The viral polymerase inhibitor 7-Deaza-2\u2032-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model","volume":"10","author":"Zmurko","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.10.034_b0215","doi-asserted-by":"crossref","first-page":"e0004658","DOI":"10.1371\/journal.pntd.0004658","article-title":"A susceptible mouse model for Zika virus infection","volume":"10","author":"Dowall","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.10.034_b0220","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.stem.2016.04.017","article-title":"Zika virus disrupts neural progenitor development and leads to microcephaly in mice","volume":"19","author":"Li","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.vaccine.2016.10.034_b0225","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2016.05.008","article-title":"Zika virus infection during pregnancy in mice causes placental damage and fetal demise","volume":"165","author":"Miner","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2016.10.034_b0230","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nature18296","article-title":"The Brazilian Zika virus strain causes birth defects in experimental models","volume":"534","author":"Cugola","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.10.034_b0235","doi-asserted-by":"crossref","first-page":"12204","DOI":"10.1038\/ncomms12204","article-title":"A rhesus macaque model of Asian-lineage Zika virus infection","volume":"7","author":"Dudley","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2016.10.034_b0240","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1016\/j.vaccine.2011.06.062","article-title":"Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO((R))) induced neutralizing antibody titers","volume":"29","author":"Van Gessel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.034_b0245","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.vaccine.2016.10.034_b0250","unstructured":"Pan American Health Organization. Case definitions; 2016. Available at: http:\/\/www.paho.org\/hq\/index.php?option=com_content&view=article&id=11117&Itemid=41532&lang=en."},{"key":"10.1016\/j.vaccine.2016.10.034_b0255","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.10.034_b0260","first-page":"172","article-title":"Abstract 576: investigations of the observed efficacy of the CYD tetravalent dengue vaccine in the Phase 2b trial in Ratchaburi, Thailand","volume":"91","author":"Jackson","year":"2014","journal-title":"Am J Trop Med Hygiene"},{"key":"10.1016\/j.vaccine.2016.10.034_b0265","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/infdis\/jis744","article-title":"Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines","volume":"207","author":"Sun","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.034_b0270","doi-asserted-by":"crossref","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2016.10.034_b0275","unstructured":"Pan American Health Organization. Zika ethics consultation: ethics guidance on key issues raised by the outbreak; 2016. Available at: http:\/\/iris.paho.org\/xmlui\/handle\/123456789\/28425."},{"key":"10.1016\/j.vaccine.2016.10.034_b0280","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","article-title":"International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines","volume":"31","author":"Dodd","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.034_b0285","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"year":"2015","series-title":"Vaccine evaluation in public health emergencies \u2013 review of regulatory pathways in selected countries","author":"WHO Expert Committee on Biological Standardization","key":"10.1016\/j.vaccine.2016.10.034_b0290"},{"key":"10.1016\/j.vaccine.2016.10.034_b0295","unstructured":"World Health Organization. Emergency use assessment and listing procedure (EUAL) for candidate vaccines for use in the context of a public health emergency; 2015. Available at: http:\/\/www.who.int\/medicines\/news\/EUAL-vaccines_7July2015_MS.pdf."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:50:04Z","timestamp":1759402204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16309690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":56,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X16309690"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}